drugset / Trial / NCT07548450
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Phase 2
Not yet recruiting
25 enrolled
University of Utah
Eli Lilly and Company · collabGenentech, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
Timeline
- Start
- 2026-06
- Primary completion
- 2034-06
- Completion
- 2035-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mosunetuzumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Pirtobrutinib | Other / unclassified | 200 mg | — |